Abstract
BackgroundThe EMBARK trial of etanercept (ETN) (NCT01258738)1 has demonstrated the long-term efficacy of ETN in patients with non-radiographic axial spondyloarthritis (nr-axSpA) and shown correlations between decreased inflammation and clinical outcomes.2ObjectivesTo...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
